Wuhan Hvsen Biotechnology Co Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.028x

Wuhan Hvsen Biotechnology Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.06 Million ≈ $8.64 Million USD) by net assets (CN¥2.12 Billion ≈ $309.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Wuhan Hvsen Biotechnology Co Ltd (2016–2025)

Cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Wuhan Hvsen Biotechnology Co Ltd for real-time trading data and today's change.

Wuhan Hvsen Biotechnology Co Ltd Cash Flow Conversion Ratio Explained

Wuhan Hvsen Biotechnology Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Wuhan Hvsen Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Wuhan Hvsen Biotechnology Co Ltd for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Shandong Shuangyi Technology Co Ltd SHE:300690	0.024x
Shenyu Communication Technology Inc SHE:300563	0.026x
Beijing Changjiu Logistics Ltd SHG:603569	-0.013x
Nagarro SE XETRA:NA9	0.166x
WPG (Shanghai) Smart Water Public Co. Ltd SHG:603956	0.020x
Invesco Trust For Inv Grade Munis NYSE:VGM	0.023x
Kambi Group PLC Series B IL:0EAW	0.056x
Veken Elite SHG:600152	0.045x

Annual Cash Flow Conversion Efficiency for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. Review Wuhan Hvsen Biotechnology Co Ltd (300871) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥2.19 Billion ≈ $319.94 Million	CN¥238.45 Million ≈ $34.89 Million	0.109x	+267.07%
2024-12-31	CN¥1.47 Billion ≈ $214.41 Million	CN¥43.53 Million ≈ $6.37 Million	0.030x	-51.74%
2023-12-31	CN¥1.51 Billion ≈ $220.86 Million	CN¥92.92 Million ≈ $13.60 Million	0.062x	-1.84%
2022-12-31	CN¥1.54 Billion ≈ $225.56 Million	CN¥96.68 Million ≈ $14.15 Million	0.063x	-34.79%
2021-12-31	CN¥1.62 Billion ≈ $236.89 Million	CN¥155.72 Million ≈ $22.79 Million	0.096x	+174.38%
2020-12-31	CN¥1.38 Billion ≈ $201.81 Million	CN¥48.35 Million ≈ $7.08 Million	0.035x	-87.40%
2019-12-31	CN¥378.28 Million ≈ $55.35 Million	CN¥105.24 Million ≈ $15.40 Million	0.278x	+327.97%
2018-12-31	CN¥324.52 Million ≈ $47.49 Million	CN¥21.10 Million ≈ $3.09 Million	0.065x	-82.00%
2017-12-31	CN¥223.11 Million ≈ $32.65 Million	CN¥80.56 Million ≈ $11.79 Million	0.361x	-6.91%
2016-12-31	CN¥154.70 Million ≈ $22.64 Million	CN¥60.00 Million ≈ $8.78 Million	0.388x	--

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology

Market Cap

$499.60 Million

CN¥3.41 Billion CNY

Market Cap Rank

#11857 Global

#3351 in China

Share Price

CN¥16.92

Change (1 day)

+0.06%

52-Week Range

CN¥16.58 - CN¥32.62

All Time High

CN¥48.84